|
A review of the device history record has been completed.No deviations or non-conformances noted.The event of capsular contracture is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event.Further information from the reporter regarding event, product, or patient details has been requested.No additional information is available at this time.Reason for reoperation: capsular contracture grade 3.
|
|
Device evaluation: per the investigation procedure, the device is analyzed through visual inspection microscopic inspection if openings are observed and a weight verification.Per the analysis performed, the assessments of the complaints and any potential manufacturing issue are displayed along with any further actions required: capsular contracture: unable to observe through visual inspection as it is a physiological phenomenon.A workmanship was observed through visual inspection not related to the complaint for a split in patch area event.A further investigation is requested.None of the other observations performed during the device analysis creases, deformation and wear abrasion are found to be potentially related to the manufacturing process, and, therefore, no further actions are required for these observations.Further investigation summary: the review of the documentation associated to the manufacturing process indicates that all devices involved in this work order were released in accordance with abbvie¿s procedures and were no defects/problems/issues found in the documents or in the personnel training related to the reported event.Additionally, no er/ ncr(s) were identified during the investigation associated with this lot and the complaint.According to the device analysis performed in the laboratory was observed split (ss) in patch area, it is out of specification per qa 199.04 the event of capsular contracture unable to observed, and the workmanship has not relation to reported complaint.Therefore, the reported events was not confirmed.A review of the current risk documents pfmea-silicone filled bi and sizer assembly, smooth rev.3.0 was performed, and the event of split in patch is a known event, for which current process controls and inspections are established to reduce the incidence of this defect.Considering that there is no adverse trend for this type of event, no additional actions are deemed required at this time.The issue with split in patch will continue to be monitored and corrective actions will be taken in the future if deemed appropriate.Additional, changed, and/or corrected data: d9, h3, h6.
|